RxSight, Inc. (NASDAQ: RXST) reported Q4 EPS of ($0.13), $0.23 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $27.88 million.

GUIDANCE:

RxSight, Inc. sees FY2024 revenue of $128-135 million, versus the consensus of $130.1 million, representing implied growth of 44% to 52% compared to 2023.
Gross margin guidance range of 65% to 67%, representing an implied increase of 500 bps to 700 bps compared to 2023.
Operating expense guidance range of $125.0 million to $128.0 million, representing an implied growth of 20% to 23% compared to 2023, and including non-cash expense guidance in the range of $22.0 million to $25.0 million.

For earnings history and earnings-related data on RxSight, Inc. (RXST) click here.